Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
Rivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
24/7 Wall St. on MSN12d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
Zacks Investment Research on MSN1d
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & MoreBayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback